Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial.
Phase II evaluation of teniposide (VM-26) in metastatic breast carcinoma. A Southeastern Cancer Study Group trial.
复制标题
替尼泊苷 (VM-26) 在转移性乳腺癌中的 II 期评估。
DOI：
10.1007/bf00170777
复制
发表时间：
1988
影响因子：
3.4
通讯作者：
Raney,M
中科院分区：
文献类型：
--
作者：
Cox,EB;Vogel,CL;CarpenterJr,JT;Raney,M
The Southeastern Cancer Study Group performed a Phase II study of teniposide in previously treated patients with metastatic breast cancer. No responses were observed in 11 evaluable patients who received teniposide 60 mg/m2by IV infusion for five consecutive days every three weeks. Toxicity was primarily gastrointestinal and hematologic and was frequently severe. This study demonstrated no therapeutic activity for teniposide when given in this dose and schedule to patients with heavily pretreated metastatic breast cancer.
